Clinical Trial News and Research

RSS

Phase 1 clinical trial: Anti-HIV antibody significantly decreases HIV levels

A single infusion of an experimental anti-HIV antibody called 3BNC117 resulted in significantly decreased HIV levels that persisted for as long as 28 days in HIV-infected individuals, according to Phase 1 clinical trial findings published online today in Nature.

8 Apr 2015

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced that clinical data for simeprevir, its NS3/4A protease inhibitor for the treatment of hepatitis C virus (HCV) infection, will be presented at The International Liver Congress 2015 of the European Association for the Study of the Liver taking place in Vienna from April 22-26.

8 Apr 2015

PAREXEL announces three new academic programs to develop global biopharmaceutical workforce

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced three new academic programs at the PAREXEL Academy.

From Parexel 8 Apr 2015

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

Rhythm, a biopharmaceutical company, and Actavis plc, a leading global pharmaceutical company, announced today the initiation of a Phase 2b clinical trial assessing the efficacy and safety of relamorelin (RM-131), Rhythm's ghrelin agonist, for the treatment of gastroparesis in patients with type 1 and type 2 diabetes.

8 Apr 2015

Exercise benefits obese, overweight people with NAFLD

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the western world. A new study published in the Journal of Hepatology shows that exercise, regardless of frequency or intensity, benefits obese and overweight adults with NAFLD.

8 Apr 2015

TOAST classification remains effective, easy-to-use system to classify strokes

In 1993, neurologists Harold P. Adams Jr., MD, and Jose Biller, MD, and colleagues proposed a new way to classify strokes. It became known as the TOAST classification. Twenty-two years later, the TOAST classification remains an effective and easy-to-use system that is routinely employed in stroke studies around the world, Drs. Adams and Biller report in the journal Stroke, published online ahead of print.

8 Apr 2015

St. Luke’s Cancer Center offers new Phase II oncolytic viral therapy clinical trial for advanced melanoma

St. Luke’s Cancer Center is a leader in offering clinical trials for patients with melanoma, the most unusual type of skin cancer and also the most deadly. Physicians such as Sanjiv Agarwala, MD, Chief of Medical Oncology and Hematology for St. Luke’s University Health Network and an internationally recognized melanoma specialist, are committed to bringing the most promising studies to the Lehigh Valley.

8 Apr 2015

Delcath expands global Phase 2 program to treat hepatocellular carcinoma

Delcath Systems, Inc. announces the expansion of its global Phase 2 program for the treatment of patients with unresectable hepatocellular carcinoma (HCC) or primary liver cancer.

7 Apr 2015

Cerapedics closes $4 million term loan, raises additional $4 million in equity financing

Cerapedics, a privately-held orthobiologics company, today announced closing of a $4 million term loan from GE Capital, Healthcare Financial Services, bringing the total facility to $16.5 million. The company also announced it recently raised an additional $4 million in equity financing from inside investors.

7 Apr 2015

Findings of Ariosa's non-invasive prenatal testing study published online in NEJM

Results from the largest clinical trial to date, comparing non-invasive prenatal testing (NIPT) using the Harmony Prenatal Test with conventional first trimester combined screening (FTS) in a general pregnancy population have been published online in The New England Journal of Medicine.

6 Apr 2015

Personalized cancer vaccines can be used to marshal powerful immune response

Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients' tumors, according to early data in a first-in-people clinical trial at Washington University School of Medicine in St. Louis.

6 Apr 2015

Clinical trial uses personalized cellular therapy to treat GVHD complication of bone marrow transplant

An innovative clinical trial using the science of "personalized" cellular therapy has begun enrolling children and adults suffering from graft-versus-host-disease (GVHD), a life-threatening complication of bone marrow transplantation in which donor immune lymphocytes attack the organs of the bone marrow transplant recipient.

3 Apr 2015

Quest Diagnostics grants Supplier Excellence Awards to five companies

Quest Diagnostics, the world's leading provider of diagnostic information services, today awarded Supplier Excellence Awards to five companies at its 2015 Supplier Forum.

From Quest Diagnostics 2 Apr 2015

Thoratec gets final FDA approval to expand enrollment of HeartMate III U.S. clinical trial

Thoratec Corporation, a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it received final approval from the FDA to broaden enrollment of the HeartMate III U.S. clinical trial of up to 1,028 patients in up to 60 sites.

2 Apr 2015

Myriad Genetics expands companion diagnostic collaboration with AstraZeneca

Myriad Genetics, Inc. today announced the expansion of its companion diagnostic collaboration with AstraZeneca. Under the terms of the expanded agreement, Myriad’s BRACAnalysis CDx test will be used to prospectively identify which patients with metastatic pancreatic cancer may respond to treatment with Lynparza (olaparib).

2 Apr 2015

Columbia Laboratories to adopt Juniper Pharmaceuticals brand marks

Columbia Laboratories, Inc., today announced that it will adopt Juniper Pharmaceuticals, Inc. as its new corporate brand. The name change will become effective Friday, April 10, 2015, and the Company's common stock will begin trading on the Nasdaq Stock Exchange under the new ticker symbol — "JNP" — on Monday, April 13, 2015.

2 Apr 2015

Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE trial

Astellas Pharma Inc. and Medivation, Inc. today announced topline results from the Phase 2 STRIVE trial comparing enzalutamide with bicalutamide in a study population of men with non-metastatic or metastatic castration-resistant prostate cancer.

2 Apr 2015

International researchers examine efficacy of rVSV-ZEBOV-GP Ebola vaccine

The World Health Organisation declared the Ebola virus outbreak a public health emergency in August 2014; since then the development of vaccines against Ebola virus has been fast tracked.

2 Apr 2015

Canada's VSV-EBOV Ebola vaccine proves safe, effective in Phase 1 clinical trial

The Honourable Rona Ambrose, Minister of Health, and Canada's Chief Public Health Officer, Dr. Gregory Taylor, today welcomed the news of promising trial outcomes of Canada's VSV-EBOV Ebola vaccine. The results of several studies and trials bring the world closer to ending this global outbreak through the provision of a commercially available vaccine.

2 Apr 2015

NIH approves $6.6 million in funding for Phase 2a adult eradication study of Argos' AGS-004

Argos Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis technology platform, today announced that the NIH Division of AIDS (DAIDS) has approved $6.6 million in funding for an investigator-initiated Phase 2a adult eradication study of AGS-004, the company’s investigational fully personalized immunotherapy for HIV.

2 Apr 2015

Clinical Trial News and Research

Phase 1 clinical trial: Anti-HIV antibody significantly decreases HIV levels

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

PAREXEL announces three new academic programs to develop global biopharmaceutical workforce

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

Exercise benefits obese, overweight people with NAFLD

TOAST classification remains effective, easy-to-use system to classify strokes

St. Luke’s Cancer Center offers new Phase II oncolytic viral therapy clinical trial for advanced melanoma

Delcath expands global Phase 2 program to treat hepatocellular carcinoma

Cerapedics closes $4 million term loan, raises additional $4 million in equity financing

Findings of Ariosa's non-invasive prenatal testing study published online in NEJM

Personalized cancer vaccines can be used to marshal powerful immune response

Clinical trial uses personalized cellular therapy to treat GVHD complication of bone marrow transplant

Quest Diagnostics grants Supplier Excellence Awards to five companies

Thoratec gets final FDA approval to expand enrollment of HeartMate III U.S. clinical trial

Myriad Genetics expands companion diagnostic collaboration with AstraZeneca

Columbia Laboratories to adopt Juniper Pharmaceuticals brand marks

Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE trial

International researchers examine efficacy of rVSV-ZEBOV-GP Ebola vaccine

Canada's VSV-EBOV Ebola vaccine proves safe, effective in Phase 1 clinical trial

NIH approves $6.6 million in funding for Phase 2a adult eradication study of Argos' AGS-004

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer